Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The ISoP Standards and Best Practices Committee.

R Bruno1, F Mentré2, S Tannenbaum3

  • 1Pharsight Consulting Services, Pharsight-a Certara Company, Marseille, France.

Clinical Pharmacology and Therapeutics
|May 21, 2014
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strengthening hospital-based vaccination models for high-risk subjects: from evidence to implementation.

Vaccine·2026
Same author

Endogenous Candida Endophthalmitis: An Update on Epidemiological, Pathogenetic, Clinical, and Therapeutic Aspects.

Ocular immunology and inflammation·2025
Same author

Excellent RAI therapeutic response on a patient presenting skull metastasis of follicular thyroid cancer after 15 years.

Endocrine·2024
Same author

Effective TRIAC treatment of a THRβ-mutated patient with thyroid hormone resistance.

Endocrine·2024
Same author

Delayed onset Bickerstaff brainstem encephalitis overlapping Miller-Fisher Syndrome during SARS-CoV-2 infection.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2023
Same author

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM).

ESMO open·2023
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
See all related articles

The International Society of Pharmacometrics Standards and Best Practices Committee aims to standardize pharmacometric analyses like population pharmacokinetics/pharmacodynamics (PK/PD) for better decision-making. The committee shares its progress and seeks volunteers for new initiatives.

Area of Science:

  • Pharmacometrics
  • Drug Development
  • Clinical Pharmacology

Background:

  • The International Society of Pharmacometrics (ISoP) Standards and Best Practices Committee was formed to address the need for standardized methodologies in pharmacometric analyses.
  • Pharmacometric analyses, including population pharmacokinetics/pharmacodynamics (PK/PD), exposure-response modeling, and disease modeling, are crucial for drug development and decision-making.

Purpose of the Study:

  • To outline the mission and ongoing progress of the ISoP Standards and Best Practices Committee.
  • To propose recommendations for standardizing pharmacometric analyses to enhance consistency, productivity, quality, communication, and impact.
  • To solicit volunteers to initiate and contribute to new standardization efforts.

Main Methods:

  • The committee's work involves developing and disseminating best practices and recommendations for various pharmacometric analyses.

Related Experiment Videos

  • Progress is reported through updates on ongoing initiatives and planned future activities.
  • Volunteer recruitment is a key method for expanding the committee's capacity and scope.

    • Main Results:

    • The committee has made progress in defining best practices for pharmacometric analyses.
    • Specific areas of focus include population PK/PD, exposure-response, and disease models.
    • A call for volunteers has been issued to drive new standardization initiatives.

    Conclusions:

    • Standardization of pharmacometric analyses is essential for improving the efficiency and impact of drug development.
    • The ISoP committee is actively working towards establishing these standards.
    • Engaging volunteers is critical for the successful implementation and expansion of these best practices.